Logo

Amgen Launches Amgevita (biosimilar- adalimumab) for the Treatment of Multiple Chronic Inflammatory Diseases in Canada

Share this
Amgen Launches Amgevita (biosimilar- adalimumab) for the Treatment of Multiple Chronic Inflammatory Diseases in Canada

Amgen Launches Amgevita (biosimilar- adalimumab) for the Treatment of Multiple Chronic Inflammatory Diseases in Canada

Shots:

  • The company reports the availability of Amgevita- referencing Humira to treat 11 chronic inflammatory conditions in Canada
  • Amgevita is available as a prefilled syringe and a prefilled pen (SureClick autoinjector) with a broad range of pack sizes to support dosing for each indication and available in a citrate-free formulation. Amgevita is reimbursed on the public drug for all indications of Humira in British Columbia- Alberta- Ontario- Quebec- New Brunswick and Newfoundland
  • The approval was based on the clinical study that supports bio-similarity with the Humira and showed no clinical differences from the reference product

  Ref: Amgen | Image: Amgen

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions